These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 36102237

  • 21. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P, Zhang J, Shang C, Zhang L.
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [Abstract] [Full Text] [Related]

  • 22. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
    Matsuda H, Hara M, Iwakami SI, Takahashi K.
    BMJ Case Rep; 2021 Apr 27; 14(4):. PubMed ID: 33906872
    [Abstract] [Full Text] [Related]

  • 23. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y, Yamamoto N, Masters ET, Kikkawa H, Mardekian J, Wiltshire R, Togo K, Ohe Y.
    Adv Ther; 2020 Jul 27; 37(7):3311-3323. PubMed ID: 32472430
    [Abstract] [Full Text] [Related]

  • 24. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
    Gao F, Gao F, Wu H, Lu J, Xu Y, Zhao Y.
    Thorac Cancer; 2022 Apr 27; 13(7):1088-1090. PubMed ID: 35212154
    [Abstract] [Full Text] [Related]

  • 25. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF, Wang WX, Xu CW, Huang LC, Li XF, Lan G, Zhai ZQ, Zhu YC, Du KQ, Lei L, Fang MY.
    Lung Cancer; 2020 Apr 27; 142():59-62. PubMed ID: 32114282
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS, Tung PH, Huang AC, Wang CC, Chang JW, Liu CY, Chung FT, Fang YF, Guo YK, Yang CT.
    BMC Cancer; 2021 Mar 24; 21(1):309. PubMed ID: 33761908
    [Abstract] [Full Text] [Related]

  • 31. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.
    Gozzi E, Angelini F, Rossi L, Leoni V, Trenta P, Cimino G, Tomao S.
    Medicine (Baltimore); 2020 Jul 02; 99(27):e21004. PubMed ID: 32629718
    [Abstract] [Full Text] [Related]

  • 32. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Masuda N, Ohe Y, Gemma A, Kusumoto M, Yamada I, Ishii T, Yamamoto N.
    Cancer Sci; 2019 Apr 02; 110(4):1401-1407. PubMed ID: 30776174
    [Abstract] [Full Text] [Related]

  • 33. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.
    Clin Cancer Res; 2014 Nov 15; 20(22):5686-96. PubMed ID: 25228534
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report.
    Chen L, Chu D, Li W, Zhang H.
    Anticancer Drugs; 2024 Jan 01; 35(1):97-100. PubMed ID: 37450292
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K, Naruse I, Shimizu K, Asao T.
    J Cancer Res Ther; 2020 Jan 01; 16(4):919-921. PubMed ID: 32930141
    [Abstract] [Full Text] [Related]

  • 38. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY.
    Eur J Cancer; 2021 Oct 01; 156():1-11. PubMed ID: 34392186
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.